CA2501584C - The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus - Google Patents

The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus Download PDF

Info

Publication number
CA2501584C
CA2501584C CA002501584A CA2501584A CA2501584C CA 2501584 C CA2501584 C CA 2501584C CA 002501584 A CA002501584 A CA 002501584A CA 2501584 A CA2501584 A CA 2501584A CA 2501584 C CA2501584 C CA 2501584C
Authority
CA
Canada
Prior art keywords
artemisinin
virus
flaviviridae
hepatitis
endoperoxides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002501584A
Other languages
English (en)
French (fr)
Other versions
CA2501584A1 (en
Inventor
Jan Vandenkerckhove
Benedikt Sas
Eric Peys
Johan Van Hemel
Johan Neyts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemin Foods LC
Original Assignee
Kemin Foods LC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemin Foods LC filed Critical Kemin Foods LC
Publication of CA2501584A1 publication Critical patent/CA2501584A1/en
Application granted granted Critical
Publication of CA2501584C publication Critical patent/CA2501584C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002501584A 2002-10-31 2003-10-29 The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus Expired - Fee Related CA2501584C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42268302P 2002-10-31 2002-10-31
US60/422,683 2002-10-31
PCT/US2003/034431 WO2004041176A2 (en) 2002-10-31 2003-10-29 The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus

Publications (2)

Publication Number Publication Date
CA2501584A1 CA2501584A1 (en) 2004-05-21
CA2501584C true CA2501584C (en) 2009-03-10

Family

ID=32312544

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002501584A Expired - Fee Related CA2501584C (en) 2002-10-31 2003-10-29 The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus

Country Status (11)

Country Link
US (1) US7842719B2 (enExample)
EP (1) EP1585524B1 (enExample)
JP (1) JP4594734B2 (enExample)
CN (1) CN100430061C (enExample)
AT (1) ATE473745T1 (enExample)
AU (1) AU2003287259A1 (enExample)
CA (1) CA2501584C (enExample)
DE (1) DE60333392D1 (enExample)
ES (1) ES2348536T3 (enExample)
PT (1) PT1585524E (enExample)
WO (1) WO2004041176A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE485039T1 (de) * 2003-02-12 2010-11-15 Univ Georgetown Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen
ES2245248B1 (es) * 2004-06-09 2007-02-16 Universidad De Salamanca Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos.
KR100824106B1 (ko) * 2006-05-30 2008-04-21 주식회사 씨티씨바이오 흰반점바이러스를 치료 또는 예방하기 위한 조성물 및 방법
WO2008010620A1 (en) * 2006-07-21 2008-01-24 Ben's Lab Co., Ltd. Composition comprising the crude drug extracts for improving liver function
US20080182895A1 (en) * 2006-08-25 2008-07-31 Howe Anita Y M Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
WO2009155379A2 (en) * 2008-06-17 2009-12-23 Hhv-6 Foundation Artemisinin and derivatives thereof as antivirals
CN102731464B (zh) * 2011-04-12 2014-07-23 沈阳药科大学 一个倍半萜内酯化合物、制备方法及其应用
US20130012470A1 (en) * 2011-07-07 2013-01-10 Humanitas Technology, LLC Antiviral compositions and methods of their use
WO2013006795A2 (en) 2011-07-07 2013-01-10 Humanitas International Foundation Antiviral compositions and methods of their use
DK2838903T3 (en) 2012-04-18 2017-12-11 Univ Hong Kong Sci & Tech Methods and Preparations for Treating Viral Infections
FR2989588A1 (fr) * 2012-04-19 2013-10-25 Centre Nat Rech Scient Composes pour la prevention ou le traitement des infections par des virus de la famille des flaviviridae
CN102755316A (zh) * 2012-07-16 2012-10-31 中国科学院武汉病毒研究所 青蒿素及其衍生物在制备治疗丙型肝炎病毒药物中的应用
US11007272B1 (en) 2016-10-07 2021-05-18 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
GB201805665D0 (en) * 2018-04-05 2018-05-23 Univ Nottingham Antiviral Compounds And Methods
US20210196676A1 (en) * 2018-05-30 2021-07-01 The Board Of Regents Of The University Of Texas System Treatment of viral infections and virally associated lesions with sequiterpene lactones
CN112245424B (zh) * 2020-10-19 2021-09-21 中国医学科学院医药生物技术研究所 一种没药烷倍半萜结构类似物在制备抗冠状病毒药物中的用途
CN112294795B (zh) * 2020-11-17 2022-03-29 北京化工大学 蒿甲醚在治疗和预防柯萨奇病毒感染中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW198722B (enExample) 1990-05-07 1993-01-21 Hoechst Ag
CN1058717A (zh) * 1990-08-08 1992-02-19 中国人民解放军军事医学科学院微生物流行病研究所 抗疟新药—复方蒿甲醚及其制备方法
CN1105238A (zh) * 1992-11-10 1995-07-19 中国预防医学科学院病毒学研究所 抗aids病毒的药物组合物
CN1035767C (zh) * 1992-11-10 1997-09-03 罗宣德 新的青蒿素衍生物及其用途
EP0713877A1 (en) 1993-07-19 1996-05-29 LUO, Xuande Qinghaosu derivatives against aids
DE4415539C2 (de) * 1994-05-03 1996-08-01 Osama Dr Dr Med Omer Pflanzen mit virustatischer und antiviraler Wirkung
CN1049435C (zh) * 1994-11-09 2000-02-16 中国科学院上海药物研究所 含苯基和杂环基的青蒿素衍生物及其制备方法
DE19902924A1 (de) 1999-01-26 2000-08-03 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur prophylaktischen und therapeutischen Behandlung von Infektionen
CN1135974C (zh) 2000-08-23 2004-01-28 重庆健桥医药开发有限公司 抗疟药新药复方双氢青蒿素
WO2002032905A1 (en) 2000-10-20 2002-04-25 Ajinomoto Co.,Inc. Medicinal compositions, dose and method for treating malaria
ATE485039T1 (de) * 2003-02-12 2010-11-15 Univ Georgetown Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen

Also Published As

Publication number Publication date
CN1711091A (zh) 2005-12-21
PT1585524E (pt) 2010-10-19
EP1585524A2 (en) 2005-10-19
CN100430061C (zh) 2008-11-05
AU2003287259A1 (en) 2004-06-07
ATE473745T1 (de) 2010-07-15
US7842719B2 (en) 2010-11-30
CA2501584A1 (en) 2004-05-21
ES2348536T3 (es) 2010-12-09
WO2004041176A3 (en) 2004-10-07
AU2003287259A8 (en) 2004-06-07
JP4594734B2 (ja) 2010-12-08
WO2004041176A2 (en) 2004-05-21
EP1585524A4 (en) 2007-10-10
EP1585524B1 (en) 2010-07-14
US20050059647A1 (en) 2005-03-17
DE60333392D1 (de) 2010-08-26
JP2006504787A (ja) 2006-02-09

Similar Documents

Publication Publication Date Title
CA2501584C (en) The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus
US20110206636A1 (en) Use of Endoperoxides for the Treatment of Infections Caused by Flaviviridae, Including Hepatitis C, Bovine Viral Diarrhea and Classical Swine Fever Virus
Momattin et al. A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Barnard et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice
KR960013435B1 (ko) 바이러스 억제제 및 dsRNA를 함유하는 바이러스 감염질환 및 HIV 감염질환 치료용 조성물
WO2016169573A1 (en) Sesquiterpene lactones as potent and broad spectrum antiviral compounds against all genotypes of hepatitis c virus (hcv)
CA2109435C (en) Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals
KR20050107490A (ko) Ｃ 형 간염 치료용 조성물
KR102133927B1 (ko) 갯까치수영 추출물 또는 이의 분획물을 유효성분으로 함유하는 수두-대상포진 바이러스 및 e형 간염 바이러스 억제용 약학적 조성물
WO2005063281A2 (de) Mittel zur hemmung der virusreplikation durch regulation der proteinfaltung
JP2008515816A (ja) カスタノスペルミンを含有する、併用抗ウイルス組成物およびその使用方法
PL190505B1 (pl) Kompozycja farmaceutyczna i sposób jej wytwarzania
CN111265527A (zh) 萘酚喹及其药学上可接受的盐在制备抗冠状病毒药物中的用途
KR20200073809A (ko) 세팔로탁신 유래 에스터 알카로이드를 유효성분으로 함유하는 헤르페스 바이러스 억제용 약학 조성물
CA2465062C (en) Preventive and/or therapeutic agent for viral infection
KR100239878B1 (ko) 간질환 예방 및 치료용 생약조성물
US20120289487A1 (en) Pharmaceutical Use of Multicyclic Compounds as Anti-Aids Agents
US11369653B2 (en) Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular disease, preparation method therefor and use thereof
US6649644B1 (en) Method of treating HIV infection by combined use of a cytotoxic agent and a non-nucleoside reverse transcriptase inhibitor
US20130302279A1 (en) Identification of natural plant extracts harboring anti-hepatitis c virus ns5b polymerase activity
KR101475630B1 (ko) 포도근 추출물 또는 이의 분획물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 조성물
KR101508294B1 (ko) 망고스틴 추출물 또는 감마, 알파 망고스틴을 유효성분으로 포함하는 ｃ형 간염의 예방 또는 치료용 조성물
WO2009084732A1 (ja) インターフェロン・リバビリン併用療法における副作用軽減剤
US20050074428A1 (en) Adjuvant agent for hepatitis C
KR100346611B1 (ko) 세코노가노사이드를포함하는비형간염치료제

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131029